Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.
NVAX
$12.38
-$0.18 -1.43%

Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.

Market News
01 Sep 2026
24/7 Wall Street
View Source
Bullish
Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.

Novavax shares rose 6% amid retail trader speculation about its Matrix-M adjuvant being used in cancer vaccines. However, the actual significant development was a quiet announcement last week that its partners received approvals for the 2026-2027 seasonal COVID-19 vaccine formulation, making Novavax eligible for royalty payments without commercial infrastructure. This royalty model, tied to partner sales led by Sanofi and Takeda, offers a steady revenue stream, while oncology applications remain exploratory with no confirmed deals. Investors should focus on upcoming milestones tied to vaccine trials and manufacturing transfers rather than speculative oncology hopes.

More News (NVAX)

Novavax jumps 22% as Sanofi advances Nuvaxovid for fall vaccinations, outpacing Moderna and BioNTech.

Novavax jumps 22% as Sanofi advances Nuvaxovid for fall vaccinations, outpacing Moderna and BioNTech.

Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather ...

Market News
Bullish
17 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App